Previous 10 | Next 10 |
HOLON, Israel , Feb. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2018 financial results on Tuesday, Februa...
Gainers: Luokung Technology (NASDAQ: LKCO ) +136% . UQM Technologies (NYSEMKT: UQM ) +46% . Staffing 360 Solutions (NASDAQ: STAF ) +24% . MYnd Analytics (NASDAQ: MYND ) +18% . Boxlight Corporation (NASDAQ: BOXL ) +15% . XTL Biopharmaceuticals (NASDAQ: XTLB ) +14% . M...
HOLON, Israel , Jan. 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the online publication of preclinical data demonstrating the role of PVRIG as a novel immune checkpoint an...
HOLON, Israel , Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting...
The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 12% gains into early January. These gains appear to be primarily based on the strength of momentum and forensic negative stock selections...
Compugen Ltd. (SUMR) Q3 2018 Results Earnings Conference Call November 07, 2018 08:30 AM ET Executives Elana Holzman - Investor Relations Dr. Anat Cohen-Dayag - President & CEO Dr. Henry Adewoye - Chief Medical Officer Ari Krashin - CFO and COO Analysts Konstantinos A...
Compugen ( CGEN ) Q3 results : Revenues: $7.8M. More news on: Compugen Ltd., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Compugen (NASDAQ: CGEN ): Q3 GAAP EPS of -$0.05 beats by $0.14 . More news on: Compugen Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOLON, Israel , Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the third quarter ended September 30, 2018 . "The last few months have been high...
HOLON, Israel , Oct. 24, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...